RYTM releases phase 3 trial data for their drug, Setmelanotide, on the 20th. Also, their chart looks very bullish. They recently broke out of their downtrend, which as you can see from the past is an extremely bullish sign. They also appear to be at the bottom of their current channel. Another bullish sign is the low volume. This means that good news could make huge moves for the stock. I anticipate at least a 13% run-up this week, and if the news is good, the stock could surge anywhere from 20-80%. I would recommend selling at the market open on Monday because bios are generally unstable during the day. However, because biotechs are very dependent on good news, my strategy for bios is to buy a certain amount and play the anticipation, then sell 1/2-3/4 of my shares on the last trading day before the press release. For this one I'm planning on only selling half of my shares on Friday, considering their past clinical trial results for this drug have been good and it is in phase 3. Like and follow if you want to see more like this :) Good Luck!
